Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells

International Journal of Cancer

Volumn 126, Issue 11, 2010, Pages 2726-2740

  Atorrasagasti, Catalina ^a   Malvicini, Mariana ^a   Aquino, Jorge B ^a,b   Alaniz, Laura ^a,b   Garcia, Mariana ^a,b   Bolontrade, Marcela ^b,c   Rizzo, Manglio ^a   Podhajcer, Osvaldo L ^b,c   Mazzolini, Guillermo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

5 FU based chemotherapy; Acidic and rich in cysteine; Cadherins; Gene therapy; Hepatocellular carcinoma; Mesenchymal to epithelial transition; Secreted protein

Indexed keywords

FLUOROURACIL; GLYCOPROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN SPARC; UNCLASSIFIED DRUG; UVOMORULIN; OSTEONECTIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOVIRUS; CELL DIVISION; CELL MOTION; CELL SURVIVAL; CLONOGENIC ASSAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; OSTEONECTIN; RECOMBINANT PROTEINS;

EID: 77951244143     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24966     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750 (Pubitemid 29114292)
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-1763
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
5. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ,for the Panel of Experts in HCCDCT. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
6. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379
7. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981;26:99-105.
8. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 1991;266:14831-14834 (Pubitemid 21907577)
9. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001;107:1049-1054
10. Mann K, Deutzmann R, Paulsson M, Timpl R. Solubilization of protein BM-40 from a basement membrane tumor with chelating agents and evidence for its identity with osteonectin and SPARC. FEBS Lett 1987;218:167-172 (Pubitemid 17090948)
11. Funk SE, Sage EH. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 1993;154:53-63.
12. Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM, Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 2005;280:36483-36493 (Pubitemid 41633922)
13. Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM, Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 2005;280:36483-36493 Epub 2005 Aug 22. (Pubitemid 41633922)
14. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001;19:816-827
15. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 1991;266:14831-14834 (Pubitemid 21907577)
16. Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C, Rempel SA. SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer 2008;122:2735-2743 (Pubitemid 351631375)
17. Hasselaar P, Sage EH. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992;49:272-283
18. Motamed K, Funk SE, Koyama H, Ross R, Raines EW, Sage EH. Inhibition of PDGFstimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem 2002;84:759-771 (Pubitemid 34113115)
19. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995;64:70-75
20. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. Overexpression of stromelysin-3. BM-40/SPARC, and. MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998;4:1375-1382
21. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997;3:171-176 (Pubitemid 27064701)
22. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006;210:459-468 (Pubitemid 44830606)
23. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:691-705.
24. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 2002;62:7357-7363 (Pubitemid 36032697)
25. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22:5021-5030 (Pubitemid 37026400)
26. Said N, Motamed K. Absence of hostsecreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005;167:1739-1752 (Pubitemid 41713324)
27. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza- 2′deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 2008;98:1810-1819 (Pubitemid 351748842)
28. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006;20:426-432 (Pubitemid 43291739)
29. Tang MJ, Tai IT. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 2007;282:34457-34467
30. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30:339-344 (Pubitemid 29125155)
31. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108:210-214 (Pubitemid 27061034)
32. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 1999;17:463-472 (Pubitemid 29421833)
33. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-1149 (Pubitemid 30159378)
34. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-524 (Pubitemid 41112921)
35. Nakatani K, Seki S, Kawada N, Kitada T, Yamada T, Sakaguchi H, Kadoya H, Ikeda K, Kaneda K. Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis. Virchows Arch 2002;441:466-474 Epub 2002 Apr 26. (Pubitemid 35430462)
36. Camino AM, Atorrasagasti C, Maccio D, Prada F, Salvatierra E, Rizzo M, Alaniz L, Aquino JB, Podhajcer OL, Silva M, Mazzolini G. Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med 2008;10:993-1004.
37. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999;189:46-52. (Pubitemid 29406818)
38. Goldenberg D, Ayesh S, Schneider T, Pappo O, Jurim O, Eid A, Fellig Y, Dadon T, Ariel I, de Groot N, Hochberg A, Galun E. Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Mol Carcinog 2002;33:113-124 (Pubitemid 34113200)
39. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003;19:207-235
40. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-811
41. Kozyraki R, Scoazec JY, Flejou JF, D'Errico A, Bedossa P, Terris B, Fiorentino M, Bringuier AF, Grigioni WF, Feldmann G. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996;110:1137-1149 (Pubitemid 26113754)
42. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002;36:692-701. (Pubitemid 34977181)
43. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann NY Acad Sci 2004;1014:155-163
44. Reed LJ MH. A simple methods of estimating fifty per cent points. Am J Hyg 1938;27:493-497
45. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
46. Aquino JB, Musolino PL, Coronel MF, Villar MJ, Setton-Avruj CP. Nerve degeneration is prevented by a single intraneural apotransferrin injection into colchicine-injured sciatic nerves in the rat. Brain Res 2006;1117:80-91.
47. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999;59:4453-4457 (Pubitemid 29418768)
48. Campo McKnight DA, Sosnoski DM, Koblinski JE, Gay CV. Roles of osteonectin in the migration of breast cancer cells into bone. J Cell Biochem 2006;97:288-302. (Pubitemid 43167146)
49. Seno T, Harada H, Kohno S, Teraoka M, Inoue A, Ohnishi T. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 2009;34:707-715
50. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005;65:7370-7377 (Pubitemid 41161270)
51. Liu J, Lian Z, Han S, Waye MM, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M, Fan D, Feitelson MA. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 2006;25:1008-1017 (Pubitemid 43277009)
52. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gammacatenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31:558-565
53. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866-3884
54. Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:523-537
55. Sage H, Johnson C, Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 1984;259:3993-4007. (Pubitemid 14170117)
56. Prieto J, Qian C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Mazzolini G, Sangro B, Kramer MG. Gene therapy of liver diseases. Expert Opin Biol Ther 2004;4:1073-1091
57. Wilson JM. Adenovirus-mediated gene transfer to liver. Adv Drug Deliv Rev 2001;46:205-209
58. Ilan Y, Saito H, Thummala NR, Chowdhury NR. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis 1999;19:49-59. (Pubitemid 29220831)
59. Yu Q, Que LG, Rockey DC Adenovirusmediated gene transfer to nonparenchymal cells in normal and injured liver. Am J Physiol Gastrointest Liver Physiol 2002;282:G565-G72.
60. Garcia-Banuelos J, Siller-Lopez F, Miranda A, Aguilar LK, Aguilar-Cordova E, Armendariz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther 2002;9:127-134
61. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004;92:679-690
62. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with plateletderived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992;89:1281-1285
63. Francki A, Motamed K, McClure TD, Kaya M, Murri C, Blake DJ, Carbon JG, Sage EH. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J Cell Biochem 2003;88:802-811 (Pubitemid 36258830)
64. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454
65. Sosa MS, Girotti MR, Salvatierra E, Prada F, de Olmo JA, Gallango SJ, Albar JP, Podhajcer OL, Llera AS. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 2007;7:4123-4134 (Pubitemid 350190284)
66. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, Sabatie E, Cano A, Garcia de Herreros A, Ballotti R, Tartare- Deckert S. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006;66:7516-7523 (Pubitemid 44289206)
67. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430